Carla J. Gargallo-Puyuelo

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Journal: Alimentary pharmacology & therapeutics

Published: March 28, 2026

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Journal: Inflammatory bowel diseases

Published: March 15, 2026

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Journal: Alimentary pharmacology & therapeutics

Published: March 14, 2026

Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.

Journal: Digestive diseases and sciences

Published: January 05, 2026

Plasma protein glycosylation: a biomarker for predicting metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.

Journal: Revista espanola de enfermedades digestivas

Published: November 17, 2025

Impact of HLADQA105 and HLADQA103 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: November 21, 2024

Predictive Score for Advanced Colorectal Neoplasia Based on Cardiovascular and Colorectal Cancer Risk Factors.

Journal: Journal of clinical medicine

Published: April 11, 2024

HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry.

Journal: The American journal of gastroenterology

Published: March 27, 2024

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.

Journal: Pharmaceutics

Published: March 25, 2024

Healthy Lifestyle Is a Protective Factor from Moderate and Severe Relapses and Steroid Use in Inflammatory Bowel Disease: A Prospective Cohort Study.

Journal: Inflammatory bowel diseases

Published: January 13, 2024

Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).

Journal: Alimentary pharmacology & therapeutics

Published: December 14, 2023

When metabolic comorbidities and risk of malnutrition coexist: The new era of inflammatory bowel disease.

Journal: The American journal of the medical sciences

Published: December 04, 2023

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.

Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.

Plasma protein glycosylation: a biomarker for predicting metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.

Plasma protein glycosylation: a biomarker for predicting metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.

Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease.

Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease.

Predictive Score for Advanced Colorectal Neoplasia Based on Cardiovascular and Colorectal Cancer Risk Factors.

Predictive Score for Advanced Colorectal Neoplasia Based on Cardiovascular and Colorectal Cancer Risk Factors.

HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry.

HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry.

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.

Healthy Lifestyle Is a Protective Factor from Moderate and Severe Relapses and Steroid Use in Inflammatory Bowel Disease: A Prospective Cohort Study.

Healthy Lifestyle Is a Protective Factor from Moderate and Severe Relapses and Steroid Use in Inflammatory Bowel Disease: A Prospective Cohort Study.

Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).

Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).

When metabolic comorbidities and risk of malnutrition coexist: The new era of inflammatory bowel disease.

When metabolic comorbidities and risk of malnutrition coexist: The new era of inflammatory bowel disease.

Impact of HLADQA105 and HLADQA103 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease.

Impact of HLADQA105 and HLADQA103 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease.